QuellTX Logo
t: 0207 096 9012
Quell Logo ×

Restoring the Balance With Regulatory T cell Therapies

Harnessing the suppressive capacity of Tregs to address immune dysfunction utilising modular engineered Tregs Addressing a range of autoimmune and inflammatory diseases as well as preventing rejection in organ transplantation

Welcome to Quell

Quell Therapeutics is a London, UK based, private biopharmaceutical company. Our vision is to be the leading engineered cell therapy company, bringing transformational and valued therapies addressing a range of autoimmune and inflammatory diseases, as well as preventing rejection in organ transplantation.

About Us

Quell was founded in partnership with six world leading experts in the field of immunology from King’s College London, University College London and Hannover Medical School. The Founders have made a significant contribution in the field of Immunology in understanding how to harness the suppressive capacity of Tregs in order to address immune dysfunction by utilising engineered Tregs.

More Info

The Science

Learn more about how we are developing transformational therapies using modular engineered Treg cell therapies for the treatment of a range of autoimmune and inflammatory diseases, as well as preventing rejection in organ transplantation.

More Info

The Pipeline

We are developing therapies addressing a range of autoimmune and inflammatory diseases, as well as preventing rejection in organ transplantation. Learn more about our pipeline of products in development.

More Info

Work With Us

Quell is a culture-led organisation which LIVES its values and we respect the diverse qualities our employees bring. Learn more about working with us.

More Info

Latest News

15/12/19

Quell Therapeutics, founded by Syncona Ltd, appoints Chief Executive

Building a team of leading experts in the field of Regulatory T cell-based therapy and biology London, 13 June 2019 – Quell Therapeutics, a biotechnology company focused on developing engineered T regulatory (Treg) cell therapies, announces the appointment of Iain McGill,…...

Read More
15/12/19

Quell Therapeutics named a “Fierce 15“ Company by FierceBiotech

London, 23 September 2019 – Quell Therapeutics, a biotechnology company focused on developing engineered T regulatory (Treg) cell therapies, announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private…...

Read More

Quell Introduction

Find out more about our vision to bring truly innovative, life changing Treg therapies for our patients as we build a major global biopharmaceutical company as well as what it’s like to work for Quell.

Quell Introduction

Find out more about our vision to bring truly innovative, life changing Treg therapies for our patients as we build a major global biopharmaceutical company as well as what it’s like to work for Quell.